

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Type or print name of person signing certification

Signature

Date

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: John Thomas Brandt

Group Art Unit: 1614

Serial No.: 10/553,763

Examiner: S. Gembeh

Application Date: April 26, 2004

Conf No.: 3837

US Nat'l Entry

Date: October 21, 2005

For: METHOD FOR TREATING CARDIOVASCULAR DISEASES

Docket No.: X-16303

RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT (37 CFR 1.121)

Commissioner for Patents

Mail Stop Missing Parts

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

This is in response to a "Notice of Non-Compliant Amendment" dated April 4, 2008.

Enclosed herewith are: 1) a copy of the Notice and 2) a corrected page 3 of our Amendment submitted on March 14, 2008.

Applicants believe there is no fee for this correction. However, if a fee is required, please charge Deposit Account No. 05-0840. The Commissioner is hereby authorized to charge any additional fees that may be required by this Response, or credit any overpayment, to Deposit Account No. 05-0840. .

Respectfully submitted,

/Francis O. Ginah/

Francis O. Ginah
Attorney for Applicants
Registration No. 44,712
Phone: 317-276-9477

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288
April 11, 2008



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

25885 e 04/04/2008

RECEIVED

APR 07 2008

Paper No.

ELI LILLY & COMPANY
PATENT DIVISION
P.O. BOX 6288
INDIANAPOLIS, IN 46206-6288

ELI LILLY AND COMPANY
Patent Division

Application No.:	10/553,763 ✓	Date Mailed:	04/04/2008
First Named Inventor:	Brandt, John, Thomas	Examiner:	GEMBEH, SHIRLEY V
Attorney Docket No.:	X16303	Art Unit:	1614
Confirmation No.:	3837 ✓	Filing Date:	10/21/2005 ✓

Please find attached an Office communication concerning this application or proceeding.

Response Due 04 May 2008

Commissioner for Patents

Notice of Non-Compliant Amendment (37 CFR 1.121)	Application No. 10/553,763	Applicant(s) BRANDT ET AL.
	Art Unit 3998	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

The amendment document filed on 14 March, 2008 is considered non-compliant because it has failed to meet the requirements of 37 CFR 1.121 or 1.4. In order for the amendment document to be compliant, correction of the following item(s) is required.

THE FOLLOWING MARKED (X) ITEM(S) CAUSE THE AMENDMENT DOCUMENT TO BE NON-COMPLIANT:

- 1. Amendments to the specification:
 - A. Amended paragraph(s) do not include markings.
 - B. New paragraph(s) should not be underlined.
 - C. Other _____.
- 2. Abstract:
 - A. Not presented on a separate sheet. 37 CFR 1.72.
 - B. Other _____.
- 3. Amendments to the drawings:
 - A. The drawings are not properly identified in the top margin as "Replacement Sheet," "New Sheet," or "Annotated Sheet" as required by 37 CFR 1.121(d).
 - B. The practice of submitting proposed drawing correction has been eliminated. Replacement drawings showing amended figures, without markings, in compliance with 37 CFR 1.84 are required.
 - C. Other _____.
- 4. Amendments to the claims:
 - A. A complete listing of all of the claims is not present.
 - B. The listing of claims does not include the text of all pending claims (including withdrawn claims)
 - C. Each claim has not been provided with the proper status identifier, and as such, the individual status of each claim cannot be identified. Note: the status of every claim must be indicated after its claim number by using one of the following status identifiers: (Original), (Currently amended), (Canceled), (Previously presented), (New), (Not entered), (Withdrawn) and (Withdrawn-currently amended).
 - D. The claims of this amendment paper have not been presented in ascending numerical order.
 - E. Other: Canceled claims 5 - 14 not listed.
- 5. Other (e.g., the amendment is unsigned or not signed in accordance with 37 CFR 1.4): For further explanation of the amendment format required by 37 CFR 1.121, see MPEP § 714.

TIME PERIODS FOR FILING A REPLY TO THIS NOTICE:

1. Applicant is given **no new time period** if the non-compliant amendment is an after-final amendment or an amendment filed after allowance, or a drawing submission (only). If applicant wishes to resubmit the non-compliant after-final amendment with corrections, the **entire corrected amendment** must be resubmitted.
2. Applicant is given **one month**, or thirty (30) days, whichever is longer, from the mail date of this notice to supply the correction, if the non-compliant amendment is one of the following: a preliminary amendment, a non-final amendment (including a submission for a request for continued examination (RCE) under 37 CFR 1.114), a supplemental amendment filed within a suspension period under 37 CFR 1.103(a) or (c), and an amendment filed in response to a Quayle action. If any of above boxes 1 to 4 are checked, the correction required is only the corrected section of the non-compliant amendment in compliance with 37 CFR 1.121.

Extensions of time are available under 37 CFR 1.136(a) only if the non-compliant amendment is a non-final amendment or an amendment filed in response to a Quayle action.

Failure to timely respond to this notice will result in:

- Abandonment of the application if the non-compliant amendment is a non-final amendment or an amendment filed in response to a Quayle action; or
- Non-entry of the amendment if the non-compliant amendment is a preliminary amendment or supplemental amendment.

Legal Instruments Examiner (LIE), if applicable /CORALIA BETANCOURT/

Telephone No: (571)272-0509

or a pharmaceutically acceptable salt thereof, ~~optionally~~ in combination with aspirin;

- b) second, performing a percutaneous coronary intervention procedure;
and
- c) third, administering a compound of formula I or a pharmaceutically acceptable salt thereof, ~~optionally~~ in combination with aspirin.

4. (Currently Amended) A method for treating acute coronary syndrome, ~~or~~ high risk vascular disease ~~or cerebrovascular aneurysm~~ and recurrence thereof, in a patient in need thereof, comprising in order the steps of:

- a) administering a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, ~~optionally~~ in combination with aspirin about 2 to 30 days prior to performing the percutaneous coronary intervention procedure,
- b) performing a percutaneous coronary intervention procedure, and
- c) administering a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, ~~optionally~~ in combination with aspirin about 0 to 365 days after performance of the percutaneous coronary intervention procedure.

Claims 5-14. (Cancelled)